Viekirax paritaprevir regulatory update

Enanta and AbbVie said the European Commission approved an all-oral, interferon-free treatment of Exviera dasabuvir and Viekirax ombitasvir/paritaprevir/ritonavir with or without ribavirin to treat chronic HCV genotype 1 infection and with ribavirin to treat chronic HCV genotype 4 infection. The combination is approved in the U.S. ...